Targeting hypoxic exosomal IGFBP2 overcomes CD47-mediated immune evasion in glioblastoma
Authors:
Open Access
- 31 January 2026
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Abstract
Glioblastoma (GBM) acquires malignant traits through complex molecular adaptations that sustain immune evasion, often characterized by hypoxia and overexpression of the phagocytosis checkpoint CD47. However, the role of hypoxic drivers coordinating CD47-dependent immune evasion remains poorly defined. Here, we integrated single cell RNA sequencing and proteomic analysis to identify that insulin-like growth factor binding protein 2 (IGFBP2) was co-expressed with CD47 in hypoxic mesenchymal-like GBM subpopulations, synergistically promoting tumor progression and immune evasion. Mechanically, hypoxia induced IGFBP2 expression via HIF-2α-mediated transcriptional activation and further increased IGFBP2-positive exosome secretion through HIF-1α-dependent RAB3A upregulation. Moreover, IGFBP2 was predominantly localized on the exosome surface via integrin α5β1 and activated integrin/FAK/STAT3 signaling to enhance CD47 expression and inhibit macrophage phagocytosis. Clinically, serum exosomal IGFBP2 levels correlated with tumor grade and could serve as a diagnostic biomarker. Importantly, combinatorial blockade of IGFBP2 and CD47 synergistically suppressed tumor growth and prolonged survival in orthotopic GBM models. Together, our findings uncovered the hypoxia-exosomal IGFBP2-CD47 axis in GBM immune evasion and provided a compelling rationale for combination therapy to improve immunotherapy efficacy in GBM.Keywords
This publication has 47 references indexed in Scilit:
- The biology and function of extracellular vesicles in immune response and immunityImmunity, 2024
- High baseline tumor burden‐associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2‐STAT3‐PD‐L1 pathwayCancer Communications, 2023
- Tumor hypoxia: From basic knowledge to therapeutic implicationsSeminars in Cancer Biology, 2023
- Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of IκBαCell Metabolism, 2022
- Blocking CD47 promotes antitumour immunity through CD103+ dendritic cell–NK cell axis in murine hepatocellular carcinoma modelJournal of Hepatology, 2022
- Hypoxia and extracellular vesicles: A review on methods, vesicular cargo and functionsJournal of Extracellular Vesicles, 2020
- IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanomaCancer Letters, 2020
- Brain malignancies: Glioblastoma and brain metastasesSeminars in Cancer Biology, 2020
- An Integrative Model of Cellular States, Plasticity, and Genetics for GlioblastomaCell, 2019
- Blocking “don't eat me” signal of CD47-SIRPα in hematological malignancies, an in-depth reviewBlood Reviews, 2018